Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00405184
Recruitment Status : Completed
First Posted : November 29, 2006
Last Update Posted : June 7, 2012
Information provided by (Responsible Party):
CSL Limited

Brief Summary:
This study aims to assess the safety, tolerability and pharmacokinetics of Ig NextGen 10% in patients with primary immune deficiency currently being treated with Intragam P. Eligible patients will switch from 3 to 4 weekly intravenous Intragam P therapy to receive seven cycles of Ig NextGen 10% treatment administered intravenously at three- to four-weekly intervals. Patients will be monitored on the study for up to 36 weeks.

Condition or disease Intervention/treatment Phase
Primary Immune Deficiency (PID) Drug: IntragamP Drug: Ig NextGen 10% Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID)
Study Start Date : May 2007
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Intervention Details:
    Drug: IntragamP
    IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
    Drug: Ig NextGen 10%
    Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.

Primary Outcome Measures :
  1. IgG Trough Pharmacokinetics [ Time Frame: one month ]

Secondary Outcome Measures :
  1. Safety and tolerability, Pharmacokinetics [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of PID
  • = or >6 month use of Intragam P at three- or four-weekly intervals
  • = or >6 month history of IgG trough levels of ≥ 5 g/L

Exclusion Criteria:

  • Newly diagnosed PID within six months prior to Screening
  • Known selective IgA deficiency or antibodies to IgA
  • Immunosuppressive treatment other than topical and/ or inhaled steroids and/ or low dose oral steroids
  • Protein-losing enteropathies, or kidney diseases
  • History of malignancies of lymphoid cells
  • Any of the following laboratory results at Screening:
  • Serum Creatinine > 1.5 times the upper normal limit (UNL)
  • AST or ALT concentration > 2.5 times the UNL
  • Albumin < 25 g/L

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00405184

Australia, South Australia
Flinders Medical Centre
Adelaide, South Australia, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Sponsors and Collaborators
CSL Limited
Principal Investigator: Karl Bleasel, Dr Melbourne Health

Publications of Results:
Responsible Party: CSL Limited Identifier: NCT00405184     History of Changes
Other Study ID Numbers: CSLCT-PID-05-22
First Posted: November 29, 2006    Key Record Dates
Last Update Posted: June 7, 2012
Last Verified: June 2012

Keywords provided by CSL Limited:

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Immune System Diseases